Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$4.00 USD
-0.40 (-9.09%)
Updated May 14, 2024 04:00 PM ET
After-Market: $4.02 +0.02 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
RAPT 4.00 -0.40(-9.09%)
Will RAPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RAPT
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%
Other News for RAPT
Roblox downgraded, Western Digital initiated: Wall Street's top analyst calls
Rapt Therapeutics just downgraded at Wolfe Research, here's why
Wolfe Research gets more bearish on Rapt Therapeutics, downgrades shares
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
Wolfe downgrades RAPT, but still sees "immense" upside potential